🔬 What is the Test?
The AML Characterization Panel is a comprehensive genetic test used to identify specific mutations and chromosomal abnormalities in Acute Myeloid Leukemia (AML). It helps classify AML subtypes, predict prognosis, and guide targeted therapy decisions.
📊 Normal Ranges:
No detectable AML-related mutations → Normal (No AML detected)
Presence of AML-associated mutations → Suggests AML, requiring further evaluation and treatment planning
(Results should be interpreted alongside clinical and laboratory findings.)
🎯 Purpose of the Test:
✅ Diagnoses AML and identifies genetic subtypes
✅ Detects key mutations like FLT3, NPM1, CEBPA, TP53, IDH1/IDH2
✅ Helps in risk stratification and prognosis assessment
✅ Guides personalized treatment options (targeted therapy, chemotherapy, or stem cell transplant)
✅ Monitors minimal residual disease (MRD) and relapse risk
🩺 When is it Recommended?
🔹 Patients suspected of having AML (fatigue, abnormal blood counts, bruising, frequent infections)
🔹 To determine AML subtype and best treatment approach
🔹 To assess prognosis and likelihood of relapse
🔹 For monitoring AML progression and response to therapy
📝 How is the Test Done?
1️⃣ Sample Collection – Blood or bone marrow sample is taken.
2️⃣ Laboratory Analysis – Advanced molecular techniques like Next-Generation Sequencing (NGS) or PCR detect genetic mutations.
3️⃣ Result Interpretation – Helps classify AML, predict treatment response, and assess prognosis.
⚠️ What Do Abnormal Results Mean?
📉 No AML Mutations Detected:
AML may not be present or may require further testing
📈 AML-Associated Mutations Detected:
Confirms AML diagnosis
Indicates specific AML subtype and prognosis
Guides treatment choices (e.g., FLT3 inhibitors for FLT3-mutated AML)
📌 Infographic Design Idea:
✔ Medical color scheme (red, white, and blue)
✔ Illustration of AML cells and genetic markers
✔ Flowchart explaining AML diagnosis and treatment pathways
✔ Table summarizing key AML mutations and their clinical significance